Data as of Mar 14
| -0.16 / -5.03%|
KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of monoclonal antibody therapeutics for diseases that represent a significant burden to society and to patients and their families. Its proprietary and patented Humaneered antibody technology, it has produced a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. It focuses on disease-specific targets and patient selection criteria in developing these drugs, the company aim to provide patients with medicines that are safe and effective and offer innovative approaches compared to current treatments. KaloBios Pharmaceuticals was founded on March 15, 2000 and is headquartered in South San Francisco, CA.
|David W. Pritchard||President, Chief Executive Officer & Director|
|Herbert C. Cross||Chief Financial & Accounting Officer|
|Geoffrey Thomas Yarranton||CSO, Executive VP-Research & Development|
|Néstor A. Molfino||Chief Medical Officer|
|Thomas C. Yonker||Head-Project Management|